Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14741MR)

This product GTTS-WQ14741MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14741MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6920MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ15867MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ14052MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ10684MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ2506MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ1128MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ1478MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ11735MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW